Association Between Hepatic Triglyceride Content and Coagulation Factors ; The Netherlands Epidemiology of Obesity Study

Objective: Whether hepatic triglyceride content (HTGC) contributes to hypercoagulability beyond total body fat (TBF) and visceral adipose tissue (VAT) is unclear. We, therefore, aimed to investigate the association between HTGC and coagulation factors (F)I (fibrinogen), VIII, IX, and XI while adjusting for TBF and VAT. Approach and Results: In this cross-sectional analysis of the NEO study (Netherlands Epidemiology of Obesity; n=6671), a random subset of participants underwent magnetic resonance imaging and magnetic resonance spectroscopy to assess VAT and HTGC (n=2580). We excluded participan... Mehr ...

Verfasser: Morelli, Vânia M.
de Mutsert, Renée
de Roos, Albert
Lamb, Hildo J.
van Hylckama Vlieg, Astrid
Bos, Mettine H.A.
Rosendaal, Frits R.
Lijfering, Willem M.
Cannegieter, Suzanne C.
Dokumenttyp: Artikel
Erscheinungsdatum: 2020
Reihe/Periodikum: Arteriosclerosis, Thrombosis, and Vascular Biology ; volume 40, issue 12, page 3004-3014 ; ISSN 1079-5642 1524-4636
Verlag/Hrsg.: Ovid Technologies (Wolters Kluwer Health)
Schlagwörter: Cardiology and Cardiovascular Medicine
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-27222177
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : http://dx.doi.org/10.1161/atvbaha.120.315365

Objective: Whether hepatic triglyceride content (HTGC) contributes to hypercoagulability beyond total body fat (TBF) and visceral adipose tissue (VAT) is unclear. We, therefore, aimed to investigate the association between HTGC and coagulation factors (F)I (fibrinogen), VIII, IX, and XI while adjusting for TBF and VAT. Approach and Results: In this cross-sectional analysis of the NEO study (Netherlands Epidemiology of Obesity; n=6671), a random subset of participants underwent magnetic resonance imaging and magnetic resonance spectroscopy to assess VAT and HTGC (n=2580). We excluded participants without complete imaging and coagulation assessment, and with history of liver disease, venous thrombosis, or on anticoagulation. Mean differences in coagulation factor levels across HTGC quartiles were estimated by linear regression adjusted for age, sex, ethnicity, education, alcohol intake, physical activity, smoking, estrogen, and menopause, in addition to TBF and VAT. Among the 1946 participants included, median HTGC was 2.66% (interquartile range: 1.34%–6.27%). Coagulation factor levels increased dose-dependently across HTGC quartiles. Mean differences between the fourth and first quartiles were 14.7 mg/dL (95% CI, 2.1–27.2) for fibrinogen, 6.7 IU/dL (95% CI, 0.5–12.9) for FVIII, 26.1 IU/dL (95% CI, 22.4–29.8) for FIX, and 8.6 IU/dL (95% CI, 4.6–12.6) for FXI. With further adjustment for TBF and VAT, the dose-response association of HTGC with FIX persisted, whereas associations with other factors disappeared. Conclusions: HTGC was associated with various coagulation factors, of which FIX remained associated with HTGC after adjustment for TBF and VAT. HTGC might contribute to venous thrombosis risk beyond total body and visceral fat through FIX levels.